Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study.


Journal

The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123

Informations de publication

Date de publication:
07 2020
Historique:
received: 03 01 2020
revised: 31 03 2020
accepted: 01 04 2020
entrez: 22 6 2020
pubmed: 22 6 2020
medline: 17 7 2020
Statut: ppublish

Résumé

Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at presentation mitigates the detrimental effect of treatment delay on symptoms. In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 1003 patients aged 14-35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 399 patients aged 16-35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis (DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from our hypotheses. We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p<0·0001) in NEDEN data and 3·846 (1·689 to 6·003; p=0·0005) in Outlook data. This was true of treatment response for all symptom types. Nevertheless, longer DUP was not associated with worse presentation for any symptoms except depression in NEDEN (coefficients 0·099 [95% CI 0·033 to 0·164]; p=0·0028 in NEDEN and 0·007 [-0·081 to 0·095]; p=0·88 in Outlook). Long DUP was associated with reduced treatment response across subscales, consistent with a harmful process upstream of individual symptoms' mechanisms; response appeared to worsen quickly at first, then more slowly. These associations underscore the importance of rapid access to a comprehensive range of treatments, especially in the first weeks after psychosis onset. UK Department of Health, National Institute of Health Research, and Medical Research Council.

Sections du résumé

BACKGROUND
Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at presentation mitigates the detrimental effect of treatment delay on symptoms.
METHODS
In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 1003 patients aged 14-35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 399 patients aged 16-35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis (DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from our hypotheses.
FINDINGS
We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p<0·0001) in NEDEN data and 3·846 (1·689 to 6·003; p=0·0005) in Outlook data. This was true of treatment response for all symptom types. Nevertheless, longer DUP was not associated with worse presentation for any symptoms except depression in NEDEN (coefficients 0·099 [95% CI 0·033 to 0·164]; p=0·0028 in NEDEN and 0·007 [-0·081 to 0·095]; p=0·88 in Outlook).
INTERPRETATION
Long DUP was associated with reduced treatment response across subscales, consistent with a harmful process upstream of individual symptoms' mechanisms; response appeared to worsen quickly at first, then more slowly. These associations underscore the importance of rapid access to a comprehensive range of treatments, especially in the first weeks after psychosis onset.
FUNDING
UK Department of Health, National Institute of Health Research, and Medical Research Council.

Identifiants

pubmed: 32563307
pii: S2215-0366(20)30147-4
doi: 10.1016/S2215-0366(20)30147-4
pmc: PMC7606908
pii:
doi:

Substances chimiques

Antipsychotic Agents 0
Dopamine Antagonists 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

602-610

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4·0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Psychol Med. 2009 Dec;39(12):1943-55
pubmed: 19627645
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Aust N Z J Psychiatry. 2017 May;51(5):455-476
pubmed: 27733710
Acta Psychiatr Scand. 1994 Jan;89(1):62-7
pubmed: 7908156
Psychol Med. 2003 Jan;33(1):97-110
pubmed: 12537041
Br J Psychiatry Suppl. 1993 Dec;(22):39-44
pubmed: 8110442
Neurosci Lett. 2018 Mar 16;669:59-67
pubmed: 27717830
Am J Psychiatry. 2016 Apr 1;173(4):362-72
pubmed: 26481174
Schizophr Bull. 2018 Oct 17;44(6):1362-1372
pubmed: 29373755
Schizophr Res. 2012 Dec;142(1-3):12-9
pubmed: 23025994
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Br J Psychiatry. 2010 May;196(5):377-82
pubmed: 20435964
Br J Psychiatry. 2006 Nov;189:446-52
pubmed: 17077436
Schizophr Res. 2012 Nov;141(2-3):215-21
pubmed: 23006501
Br J Psychiatry. 2008 Sep;193(3):203-9
pubmed: 18757977
Psychiatry Res. 2014 Nov 30;219(3):420-5
pubmed: 24999174
Arch Gen Psychiatry. 2008 Jun;65(6):634-40
pubmed: 18519821
Br J Psychiatry. 2000 Dec;177:511-5
pubmed: 11102325
Psychol Med. 2018 Jul;48(10):1592-1607
pubmed: 29173201
Psychiatry Res. 2011 May 15;187(1-2):42-8
pubmed: 21168920
J Psychiatr Res. 2016 Jun;77:15-21
pubmed: 26950643
Arch Gen Psychiatry. 2005 Sep;62(9):975-83
pubmed: 16143729
Br J Psychiatry. 2013 Jan;202(1):35-41
pubmed: 23174515
Early Interv Psychiatry. 2014 Feb;8(1):59-67
pubmed: 23347742
Br J Psychiatry. 2014 Aug;205(2):88-94
pubmed: 25252316

Auteurs

Richard J Drake (RJ)

Division of Psychology & Mental Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, UK. Electronic address: richard.drake@manchester.ac.uk.

Nusrat Husain (N)

Division of Psychology & Mental Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; Lancashire Care & South Cumbria NHS Foundation Trust, Preston, Lancashire, UK.

Max Marshall (M)

Lancashire Care & South Cumbria NHS Foundation Trust, Preston, Lancashire, UK.

Shôn W Lewis (SW)

Division of Psychology & Mental Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, UK.

Barbara Tomenson (B)

Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK.

Imran B Chaudhry (IB)

Division of Neuroscience & Experimental Psychology, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; Department of Psychiatry, Ziauddin University, Karachi, Pakistan.

Linda Everard (L)

Birmingham and Solihull NHS, Mental Health Foundation, Trust, Birmingham, UK.

Swaran Singh (S)

Department of Mental Health & Wellbeing, University of Warwick, Warwick, UK.

Nick Freemantle (N)

Institute for Clinical Trials, University College London, London, UK.

David Fowler (D)

School of Psychology, University of Sussex, Brighton, UK; Sussex Partnership NHS Foundation Trust, Worthing, UK.

Peter B Jones (PB)

Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK; NIHR Collaboration for Leadership in Applied Health Research & Care East of England, Cambridge, UK.

Tim Amos (T)

School of Clinical Sciences, University of Bristol, Bristol, UK; Avon & Wiltshire Mental Health Partnership NHS Trust, Chippenham, UK.

Vimal Sharma (V)

Chester Medical School, University of Chester, Chester, UK; Cheshire & Wirral Partnership NHS Foundation Trust, Chester, UK.

Chloe D Green (CD)

Manchester Academic Health Science Centre, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, UK.

Helen Fisher (H)

MRC Centre for Social, Genetic & Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; NIHR Maudsley Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Til Wykes (T)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; NIHR Maudsley Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Iain Buchan (I)

Division of Informatics, Imaging & Data Sciences, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Salford Royal NHS Foundation Trust, Salford, UK; Institute of Population Health Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.

Max Birchwood (M)

Department of Mental Health & Wellbeing, University of Warwick, Warwick, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH